S-100B Protein and Chronic Subdural Hematoma

it usually points to a predisposing factor, as in this case, where a brain metastasis led to the formation of a hematoma (GelabertGonzález et al., 2012). Moreover, while the radiological image of the patient in their study shows a hematoma, it is of small and therefore leads one to question how this can be responsible for such a midline shift. This suggests that something more must be involved, as was revealed at autopsy where a metastases was identified. In a recent paper, Kruijff and Hoekstra (2012) state that the protein S-100B is probably the best biomarker for melanoma, having potential to identify high-risk stage III melanoma patients who may benefit from adjuvant systematic treatment. Since an effective (adjuvant) therapy for locoregional metastatic and disseminated melanoma has only been recently introduced, the diagnostic of S-100B, they argue, is set to increase in the near future. It therefore appears inappropriate to consider differential levels of S-100B as indicative of the evolution of CSH, as suggested by the paper’s title, since they can be more indicative of a melanoma and its metastasis. A commentary on